Trial site
Diakonie-Klinikum Schwaebisch Hall gGmbH
Schwaebisch Hall, 74523, GermanyNot linked to an institution yet
- 9running trials
- 3closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 22 trials
- Phase 41 trial
- Status
- Recruiting6 trials
- Active, not recruiting3 trials
- Completed3 trials
- Lead sponsor
- University of Heidelberg Medical Center2 trials
- AstraZeneca1 trial
- Daiichi Sankyo1 trial
- Epizyme, Inc.1 trial
- Goethe University1 trial
- and 6 more
Running trials
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· Phase 3· Daiichi Sankyo· Source
Recruiting
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT05460000· Phase 2· North Eastern German Society of Gynaecological Oncology· Source
Active, not recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
2023-507402-13-00· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094· Phase 2· Goethe University· Source
Recruiting
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
NCT05362760· Phase 4· Prof. Wolfgang Janni· Source
Recruiting
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT05255653· Phase 3· Leiden University Medical Center· Source
Active, not recruiting
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· Phase 3· Epizyme, Inc.· Source
Active, not recruiting
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03617731· Phase 3· University of Heidelberg Medical Center· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error